Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aslan Pharmaceuticals Ltd ADR (ASLN)

Aslan Pharmaceuticals Ltd ADR (ASLN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,360
  • Shares Outstanding, K 69,745
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,320 K
  • 60-Month Beta 1.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.84
Trade ASLN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.70
  • Most Recent Earnings -0.16 on 10/28/22
  • Next Earnings Date 11/01/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 91.83%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 985.60% on 11/25/22
  • IV Low 0.00% on 11/30/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 0
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 194
  • Open Int (30-Day) 198

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.19
  • Number of Estimates 2
  • High Estimate -0.18
  • Low Estimate -0.20
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3405 +64.46%
on 11/02/22
0.6100 -8.20%
on 11/29/22
+0.1599 (+39.97%)
since 10/28/22
3-Month
0.3405 +64.46%
on 11/02/22
0.8450 -33.73%
on 09/12/22
-0.1790 (-24.22%)
since 08/30/22
52-Week
0.3405 +64.46%
on 11/02/22
1.5700 -64.33%
on 12/07/21
-0.9700 (-63.40%)
since 11/26/21

Most Recent Stories

More News
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study

Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.

ANGN : 0.8601 (-2.09%)
NBRV : 2.06 (+1.23%)
ASLN : 0.5575 (+1.36%)
IMCR : 62.94 (+4.08%)
Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal

Axsome's (AXSM) phase III ACCORD study evaluating AXS-05 for treating Alzheimer's disease agitation met the primary and key secondary endpoints. Shares rise.

ANGN : 0.8601 (-2.09%)
AXSM : 72.93 (+2.95%)
ASLN : 0.5575 (+1.36%)
IMCR : 62.94 (+4.08%)
Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why

Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.

ANGN : 0.8601 (-2.09%)
EDIT : 9.76 (-1.71%)
ASLN : 0.5575 (+1.36%)
IMCR : 62.94 (+4.08%)
Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now

Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

ANGN : 0.8601 (-2.09%)
ASLN : 0.5575 (+1.36%)
IMVT : 13.15 (+3.54%)
IMCR : 62.94 (+4.08%)
Seagen (SGEN) Adcetris Label Expansion OK'd, New CEO Named

The FDA approves Seagen's (SGEN) Adcetris for a new indication, treating pediatric patients with previously untreated high-risk Hodgkin lymphoma. The company also appoints a new CEO.

AMRN : 1.1400 (unch)
SGEN : 119.30 (+1.64%)
AGLE : 0.4697 (-61.50%)
ASLN : 0.5575 (+1.36%)
Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus

Kodiak Sciences (KOD) reports a narrower-than-expected loss for the third quarter of 2022. The focus is on the lead candidate, KSI-301, developed for treating various retinal vascular diseases.

REGN : 737.92 (+0.25%)
BAYRY : 14.4301 (-0.77%)
ASLN : 0.5575 (+1.36%)
KOD : 7.14 (+1.61%)
Halozyme's (HALO) Q3 Earnings and Revenues Surpass Estimates

Halozyme's (HALO) earnings and revenues beat estimates for the third quarter of 2022.

RHHBY : 40.7500 (+0.22%)
JNJ : 175.70 (-0.22%)
HALO : 56.84 (-0.37%)
ASLN : 0.5575 (+1.36%)
Apellis' (APLS) Q3 Earnings Miss Estimates, Revenues Top Mark

Apellis' (APLS) earnings miss estimates in the third quarter of 2022 while revenues beat the same.

AZN : 67.02 (+1.42%)
AMRN : 1.1400 (unch)
APLS : 50.05 (-0.14%)
ASLN : 0.5575 (+1.36%)
ASLAN PHARMACEUTICALS SIGNS LICENSE AGREEMENT WITH BELLE.AI TO USE BELLESTUDY™ IMAGE CAPTURE SOFTWARE IN ATOPIC DERMATITIS CLINICAL TRIALS

/PRNewswire/ -- BelleTorus Corporation ("Belle.ai") and ASLAN Pharmaceuticals (Nasdaq: ASLN), today announced that ASLAN has licensed belleStudy™ digital image...

ASLN : 0.5575 (+1.36%)
ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis

MENLO PARK, Calif. and SINGAPORE, June 07, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused...

ASLN : 0.5575 (+1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003...

See More

Key Turning Points

3rd Resistance Point 0.6892
2nd Resistance Point 0.6496
1st Resistance Point 0.5998
Last Price 0.5575
1st Support Level 0.5104
2nd Support Level 0.4708
3rd Support Level 0.4210

See More

52-Week High 1.5700
Fibonacci 61.8% 1.1003
Fibonacci 50% 0.9553
Fibonacci 38.2% 0.8102
Last Price 0.5575
52-Week Low 0.3405

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar